Biotech Regulatory Strategy Before Fundraising

Regulatory strategy is often treated as a later-stage task. For fundraising, that can be a costly mistake. Investors are not only evaluating whether the science is exciting; they are evaluating whether the development path is understandable and whether the financing ask is sufficient to reach the next meaningful milestone.

Device classification can determine whether a company is planning for exemption, 510(k), De Novo, or PMA. A diagnostic's intended use can change validation requirements. A therapeutic's IND-enabling package and CMC plan can shape millions of dollars of spending. If the pathway is wrong, the fundraising model can be wrong.

Early companies do not need every regulatory question answered. They do need to demonstrate that the major pathway assumptions have been investigated and that uncertainty is acknowledged.

• Product classification or development category
• Likely submission or interaction pathway
• Key preclinical, analytical, clinical, or validation requirements
• Major regulatory risks and decision points
• Planned FDA interactions where uncertainty is material
• Budget and timeline implications
  

A credible regulatory plan turns a vague use of proceeds into a development plan. Instead of 'raise $4 million for product development,' a company can show what the financing will achieve, which regulatory gates will be crossed, and what evidence will exist at the end.

BYB Takeaway

Before fundraising, know enough about the regulatory path to explain what the money will accomplish, what could change the plan, and why the proposed milestones matter.

A regulatory strategy should improve the financing story because it improves the development story.